Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

RNXT

+ Watchlist+ Portfolio

RenovoRx, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.04
52-Week Range
$0.76 – $2.59
Market Cap
$54.04M
P/E (TTM)
—
EPS (TTM)
-0.31
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.80
PEG Ratio
—
Return on Equity
-149.98%
Return on Assets
-68.60%
Gross Margin
84.04%
Operating Margin
-467.43%
Profit Margin
0.00%
Current Ratio
5.65
Debt/Equity
0.04
Total Debt
$358.00K
Free Cash Flow
$-6.84M
Revenue Growth
300.80%
Earnings Growth
—
Enterprise Value
$43.99M

Market Snapshot

About

RenovoRx is a clinical-stage biopharmaceutical company developing targeted combination therapies for high unmet medical need cancers. The company focuses on intra-arterial delivery technology that enables localized, intensive treatment of tumors while minimizing systemic exposure. RenovoRx is advancing its pipeline with a focus on pancreatic cancer and other solid tumors.